Download PDF
Horm Metab Res 2003; 35(7): 427-433
DOI: 10.1055/s-2003-41624
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Soluble Tumour Necrosis Factor-α Receptor I and Interleukin-6 as Markers of Activity in Thyrotoxic Graves' Disease

R.  Pichler 1 , W.  Maschek 1 , M.  Hatzl-Griesenhofer 1 , H.  Huber 1 , C.  Crespillo-Gómez 2 , J.  Berg 3
  • 1Institute of Nuclear Medicine and Endocrinology, General Hospital Linz, Austria
  • 2Complejo Hospitalario Carlos Haya, Málaga, Spain
  • 3Institute of Laboratory Medicine, General Hospital Linz, Austria
Further Information

Publication History

Received 2 December 2002

Accepted after Revision 11 March 2003

Publication Date:
21 August 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Autoimmune thyroid diseases are thought to be mediated by pro-inflammatory cytokines such as TNFα and IL-6. Serum levels of cytokines may indicate activity levels of immune functions. We investigated serum levels of IL-6 and of the soluble receptor of TNFα in patients with newly diagnosed onset of Graves' hyperthyroidism. The predominantly female group consisted of 39 patients, mean fT4 was 47.6 pg/ml (normal values 7.5 - 19.0 pg/ml). After diagnosis, all patients were treated with anti-thyroid drugs. Soluble Tumour Necrosis Factor Receptor I (TNF-RI) serum levels were found significantly increased (mean 3.7 ± 1.3 ng/ml; p < 0,01) compared to a matched group of apparent healthy individuals (mean sTNF-RI 1.8 ± 0.5 ng/ml) and to a matched group of patients with treated Graves' disease (mean sTNF-RI 1.9 ± 0.6 ng/ml). When IL-6 was assessed only 4 of the 39 patients exhibited increased serum levels. Our finding may indicate that sTNF-RI and possibly its ligand, TNFα, could play an important role in the onset of the acute stage of Graves' disease.

Key words

TNF receptor - Cytokines - Hyperthyreosis - Graves' disease

References

  • 1 Roura-Mir C, Catálfamo M, Sospedra M, Alcalde L, Pujol-Borrell R, Jaraquemada D. Single-cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto's and Graves' disease.  Eur J Immunol. 1997;  27 3290-3302
    PubMedGoogle Scholar
  • 2 Hunt P J, Marshall S E, Weetman A P, Bell J I, Wass J AH, Welsh K I. Cytokine gene polymorphisms in autoimmune thyroid disease.  J Clin Endocrinol Metab. 2000;  85 1984-1988
    CrossrefPubMedGoogle Scholar
  • 3 Rasmussen A K, Hartoft-Nielsen M, Feldt-Rasmussen U. Models to study the pathogenesis of thyroid autoimmunity.  Biochimie. 1999;  81 511-515
    CrossrefPubMedGoogle Scholar
  • 4 Ajjan R A, Watson P F, Weetman A P. Cytokines and thyroid function.  Adv Neuroimmunol. 1996;  6 359-386
    PubMedGoogle Scholar
  • 5 Aust G, Heuer M, Laue S, Lehmann I, Hofmann A, Heldin N E, Scherbaum W A. Expression of tumour necrosis factor-alpha (TNF-alpha) mRNA and protein in pathological thyroid tissue and carcinoma cell lines.  Clin Exp Immunol. 1996;  105 148-154
    CrossrefPubMedGoogle Scholar
  • 6 Nophar Y, Kemper O, Brakebush C, Englemann H, Zwang R, Aderka D, Holtmann H, Wallach D. Soluble forms of human necrosis factor (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form encodes both the cell surface and a soluble form of the receptor.  Eur Molec Biol Organ J. 1990;  9 3269-3273
    PubMedGoogle Scholar
  • 7 Hohmann H P, Remy R, Brockhaus M, van Loon A PGM. Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha).  J Biol Chem. 1989;  264 14 927-14 934
    PubMedGoogle Scholar
  • 8 Pang X P, Yoshimura M, Hershman J M. Suppression of rat thyrotroph and thyroid cell function by tumor necrosis factor-alpha.  Thyroid. 1993;  3 325-330
    PubMedGoogle Scholar
  • 9 Siddiqi A, Monson J P, Wood D F, Besser G M, Burrin J M. Serum cytokines in thyrotoxicosis.  J Clin Endocrinol Metab. 1999;  84 435-439
    CrossrefPubMedGoogle Scholar
  • 10 Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall J R, Roti E. Serum concentrations of proinflammatory cytokines in Graves's disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking.  Europ J Endocrinol. 2000;  143 197-202
    PubMedGoogle Scholar
  • 11 Komiya I, Yamada T, Sato A, Kouki T, Nishimori T, Takasu N. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin-13.  J Clin Endocrinol Metab. 2001;  86 3540-3544
    CrossrefPubMedGoogle Scholar
  • 12 Celik I, Akalin S, Erbas T. Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment.  Eur J Endocrinol. 1995;  132 668-672
    PubMedGoogle Scholar
  • 13 Akalin A, Colak Ö, Alatas Ö, Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism.  Clin Endocrinol. 2002;  57 125-129
    CrossrefPubMedGoogle Scholar
  • 14 Lantz M, Malik S, Slevin M L, Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans.  Cytokine. 1990;  2 402-406
    CrossrefPubMedGoogle Scholar
  • 15 Diez-Ruiz A, Tilz G P, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis.  Eur J Haematol. 1995;  54 1-8
    PubMedGoogle Scholar
  • 16 Modzelewski B. Release of tumor necrosis factor alfa and its soluble receptor p55 in clinical septic syndrome.  Arch Immunol Ther Exp. 1997;  45 213-219
    PubMedGoogle Scholar
  • 17 Bartalena L, Brogioni S, Grasso L, Martino E. Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration.  J Endocrinol Invest. 1993;  16 213-218
    PubMedGoogle Scholar
  • 18 Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis.  Arthritis Rheum. 1997;  40 1096-1105
    PubMedGoogle Scholar
  • 19 Herrmann W, Ecker D, Quast S, Klieden M, Rose S, Marzi I. Comparison of procalcitonin, sCD14 and interleukin-6 values in septic patients.  Clin Chem Lab Med. 2000;  38 41-46
    CrossrefPubMedGoogle Scholar
  • 20 Pichler R, Berg J, Crespillo C, Hatzl-Griesenhofer M, Huber H, Maschek W. Hipertiroidismo de Graves y modulación por citoquinas proinflamatorias: el papel de TNF-R e IL-6 en la fase aguda.  Endocrinología. 2001;  48 (supl. 2) 53 (abstract)
    PubMedGoogle Scholar
  • 21 Fraunberger P, Pfeiffer M, Cremer P, Holler E, Nagel D, Dehart I, Thein M, Walli A K, Seidel D. Validation of an automated enzyme immunoassay for Interleukin-6 for routine clinical use.  Clin Chem Lab Med. 1998;  36 797-801
    CrossrefPubMedGoogle Scholar
  • 22 Heilig B, Wermann M, Gallati H, Brockhaus M, Berke B, Egen O, Pezzutto A, Hunstein W. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis.  Clin Investig. 1992;  70 22-27
    CrossrefPubMedGoogle Scholar
  • 23 Mariotti S, Caturegli P, Barbesino G, Marino M, Del Prete G F, Chiovato L, Tonacchera M, de Carli M, Pinchera A. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases.  Clin Endocrinol. 1992;  37 415-422
    PubMedGoogle Scholar
  • 24 Smallridge R C, Tsokos G C, Burman K D, Porter L, Cranston T, Sfikakis P P, Solomon B L. Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis.  Clin Diagn Lab Immunol. 1997;  4 583-586
    PubMedGoogle Scholar
  • 25 Díez J J, Hernanz A, Medina S, Bayón C, Iglesias P. Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function.  Clin Endocrinol. 2002;  57 515-521
    CrossrefPubMedGoogle Scholar
  • 26 Komorowski J, Jankiewicz J, Robak T, Blasinska-Morawiec M, Stepien H. Cytokines serum levels as the markers of thyroid activation in Graves' disease.  Immunol Lett. 1998;  60 143-148
    CrossrefPubMedGoogle Scholar
  • 27 Wakelkamp I MMJ, Gerding M N, van der Meer J WC, Prummel M F, Wiersinga W M. Both Th1 and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy.  Clin Exp Immunol. 2000;  121 453-457
    CrossrefPubMedGoogle Scholar
  • 28 Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease.  J Clin Endocrinol Metab. 1994;  78 98-102
    CrossrefPubMedGoogle Scholar
  • 29 Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr W R. et al . Prospective multicenter study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease.  Acta Endocrinol. 1989;  120 689-701
    PubMedGoogle Scholar
  • 30 Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R. Prediction of Remission or Relapse for Graves' Hyperthyroidism by the Combined Determination of Stimulating, Blocking and Binding TSH-Receptor Antibodies after the Withdrawal of Antithyroid Drug Treatment.  Horm Metab Res. 2002;  34 383-388
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Nygaard B, Jarlov A E, Kristensen L O, Faber J. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.  Horm Metab Res. 2000;  32 283-287
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Heufelder A E. Pathogenesis of Graves' ophthalmopathy: recent controversies and progress.  Eur J Endocrinol. 1995;  132 532-541
    PubMedGoogle Scholar
  • 33 Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy.  J Clin Endocrinol Metab. 2000;  85 1194-1199
    CrossrefPubMedGoogle Scholar
  • 34 Mysliwiec J, Kretowski A, Topolska J, Siewko K, Jakubczyk D, Szelachowska M, Mikita A, Kinalska I. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.  Horm Metab Res. 2001;  33 739-743
    Article in Thieme ConnectPubMedGoogle Scholar

R. Pichler, M. D., Ph. D. 

Institute of Nuclear Medicine and Endocrinology, AKH Linz

Krankenhausstr. 9 · 4020 Linz · Austria

Phone: +43(70)7806-6144

Fax: +43(70)7806-6165

Email: Robert.Pichler@akh.linz.at